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 ABSTRACT 
 
Background:  Although pain after laparoscopic surgery is less          
intense than open surgery, some patients still experience 
considerable discomfort. The aim of this project is to study the 
influence of intraperitoneal instillation of bupivacaine on pain 
after laparoscopic surgery, since there is some controversy in 
recent trials.  
 
Methods 
 
       In this study 120 patients qualified for laparoscopic abdominal 
surgery were randomized to four groups. Group A received 2mg/ kg 
of bupivacaine in 60ml of normal saline immediately after creation of 
pneumoperitoneum. Group B received 2mg  / kg of bupivacaine in 
60ml of normal saline at the end of planned surgical procedure. Group 
C received 60 ml of normal saline immediately after creation of 
pneumoperitoneum. Group D received 60ml of normal saline 
immediately after creation of pneumoperitoneum. Group D received 
60ml of normal saline at the end of planned surgical procedure. The 
patients with ASA grade III or more and patient who had 
hypersensitivity to bupivacaine were excluded from the study. 
 
 
  
The primary end points of the study were post operative pain 
intensity on a visual analog scale and incidence of shoulder tip pain. 
The secondary end points includes the latency of nurse – controlled 
analgesia activation, the analgesia request rate and analgesic 
consumption.  
 
Results : 
Significantly lower visual analog scores were observed in group 
A versus group C and B versus D during the initial 24 and 48 hr. 
respectively. The patients in group A versus group B reported 
significantly lower pain at 4 hour (p < 0.001) and 8h (p = 0.003) post – 
operatively, but the difference was not significant after 12,24 and 48 
hour. None of the group A patients reported shoulder tip pain, 
whereas it was reported by 3 patients in group B, 6 patients in group 
C, 7 Patients in group D (P <0.01). The latency of nurse controlled 
analgesia activation was 426.8 ± 57.2 min. Group A as compared with 
307 ± 39.8 min in group B, 109.3 ± 51 in group C and 109 ± 46.5 min in 
group D (p<0.001). A significantly lower analgesia request rate was 
observed in group A versus C, as compared with group B versus D, 
throughout the entire study  period (p<0.05). 
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INTRODUCTION 
 
 
Although laparoscopic surgery is associated with less pain than 
contemporary open procedures, it is definitely not pain free and the 
magnitude of postoperative shoulder and abdominal pain in the early 
postoperative period is still quite significant. This postoperative pain is a 
major concern not only for the patients, but also healthcare workers; and 
it often contributes to overnight hospital stay after this minimally 
invasive surgical procedure.  
 
The severe pain we encountered in the laparoscopy patients 
during their post operative period  may be secondary to tissue injury. 
One possibility is peritoneal irritation largely due to 1) CO2 pressure in 
the abdomen, 2) blood left in the abdomen after surgery, and 3) 
diaphragmatic irritation. A higher intraperitoneal CO2 pressure has been 
shown to generate more intense pain compared with a lower one, and 
laparoscopic procedures done without CO2 insufflation at all are 
associated with less pain. In addition, surgery closer to the diaphragm 
has been shown to cause more pain than that following manoeuvres at 
lower sites in the abdomen. Another possible source of pain in the 
laparoscopy patients is pain from sustained intraoperative pressure on 
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capillary beds in the abdominal and possibly retroperitoneal viscera, 
causing nociception but resolves over the first few postoperative hours. 
Intraperitoneal instillation of local anaesthetics at the time of 
surgery to control pain after laparoscopic surgery has been extensively 
studied in numerous randomized trials and found to  have conflicting 
results. To answer this question, we  designed a prospective randomized 
controlled trial with the specific aim  to study the analgesic effect of    
intraperitoneal bupivacaine in the postoperative setting after 
laparoscopic surgery. If we can improve pain control after this minimally 
invasive procedure, it might result in decreased postoperative 
requirement of narcotic ,NSAIDS analgesia and its associated side-
effects. It may also result in early recovery and the same day discharge of 
the patients with significant cost-containment for the patient and 
healthcare systems in future. 
In the future remote handling technology will overcome the 
manipulative restriction in the current instruments thereby indirectly 
reduce the post operative pain. 
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AIM 
 
¾ To study the post operative analgesic effect of intraperitoneal 
bupivacaine instillation in laparoscopic surgery. 
 
¾ To compare the analgesic effect of intraperitoneal bupivacaine 
instillation immediately after the creation of pneumoperitoneum 
and at the end of planned surgical procedure. 
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REVIEW OF LITERATURE 
 
HISTORY OF LAPAROSCOPIC SURGERY 
1901 : 
  The first experimental laparoscopy was performed in Berlin by 
German surgeon Georg Kelling,  
1910   
H.C. Jacobaeus of Stockholm published a discussion of the 
inspection of the peritoneal, pleural and pericardial cavity. 
1911  
Bertram M. Bernheim, from Johns Hopkins Hospital introduced 
first laparoscopic surgery to the United States. He named the procedure 
of minimal access surgery as "organoscopy". The instrument used was a 
proctoscope of a half inch diameter and ordinary light for illumination 
was used. 
1911 
  H.C. Jacobaeus, again coined the term "laparothorakoskopie" 
after using this procedure on the thorax and abdomen.   
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1918 
 O. Goetze, developed an automatic pneumoperitoneum needle 
characterized for its safe introduction to the peritoneal cavity. 
1920 
Zollikofer of Switzerland discovered the benefit of CO2 gas to use 
for insufflation, rather than filtered atmospheric air or nitrogen. 
1929 
  Kalk, a German physician, introduced the forward oblique (135 
degree) view lens systems. Goetze of Germany first developed a needle 
for insufflations. 
1929 (2) 
  Heinz Kalk, a German gastroenterologist developed a 135 degree 
lens system and a dual trocar approach.  
1934 
  John C. Ruddock, an American surgeon described laparoscopy as 
a good diagnostic method, many times, superior than laparotomy.  John 
C. Ruddock used the instrument for diagnostic laparoscopy which 
consisted a built-in forceps with electro coagulation capacity. 
 6
1936 
 Boesch of Switzerland is credited for doing the first laparoscopic 
tubal sterilization 
1938 
  Janos Veress of Hungary developed a specially designed spring-
loaded needle, called veress needle.   
1939 
  Richard W. Telinde, tried to perform an endoscopic procedure by 
a culdoscopic approach, in the lithotomy position.  
1939 
  Heinz Kalk published his experience of 2000 liver biopsies 
performed using local anaesthesia without mortality. 
1953 
  The rigid rod lens system was discovered by Professor Hopkins. 
The credit of videoscopic surgery goes to this surgeon who has 
revolutionized the concept by making this instrument. 
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1960 
  Kurt Semm, a German gynaecologist, who invented the automatic 
insufflator. 
1960 
British Gynaecologist Patrick Steptoe adapted the techniques of 
sterilization by two puncture technique. 
1972 
H.Coutnay Clarke first time showed laparoscopic suturing 
technique for hemostasis. 
1973 
Gaylord D. Alexander developed techniques of safe local and 
general anaesthesia suitable for laparoscopy. 
1977 
First Laparoscopic assisted appendicectomy was performed by 
Dekok. Appendix was exteriorized and ligated outside. 
1977 
Kurt Semm first time demonstrated endoloop suturing technique 
in laparoscopic Surgery.   
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 1978 
Hasson proposed a blunt mini-laparotomy which permits direct 
visualization of trocar entrance into the peritoneal cavity. 
1980 
In United Kingdom Patrick Steptoe, started to perform 
laparoscopic procedures. 
1983 
Semm, a German gynaecologist, performed the first laparoscopic 
appendicectomy. 
1985  
The first documented laparoscopic cholecystectomy was 
performed by Erich Mühe in Germany in 1985.  
1987 
Ger reported first laparoscopic repair of inguinal hernia using 
prototype stapeler. 
1987 
Phillipe Mouret, has got the credit to perform the first laparoscopic 
cholecystectomy in Lyons, France using video technique. 
Cholecystectomy is the laparoscopic procedure which revolutionized the 
general surgery. 
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1988 
Harry Reich performed laparoscopic lymphadenectomy for 
treatment of ovarian cancer. 
1989 
Harry Reich described first laparoscopic hysterectomy using 
bipolar dessication; later he demonstrated staples and finally sutures for 
laparoscopic hysterectomy. 
1989 
Reddick and Olsen reported that CBD injury after laparoscopic 
cholecystectomy is 5 times that with conventional cholecystectomy.  
1990 
Bailey and Zucker in USA popularized laparoscopic anterior 
highly selective vagotomy com1994, A robotic arm was designed to hold 
the telescope with the goal of improving safety and reducing the need of 
skilled camera operator. 
1996 
First live telecast of laparoscopic surgery performed remotely via 
the Internet.  (Robotic Telesurgery). 
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NOCICEPTIVE PAIN 
Nociceptive pain is caused by an injury to body tissues.  
Nociceptive pain occurs as a result of the activation of the 
nociceptive system by noxious stimuli that can cause mechanically, 
chemically, or thermally induced damage to tissue integrity. The 
nociceptive system originates in peripheral tissues, spans the spinal 
cord, traverses the brain stem and thalamus, and terminates in the 
cerebral cortex, where the sensation of pain is perceived. Peripheral 
tissues are innervated by nociceptors, highly specialized primary sensory 
neurons, which contain specific receptors or ion channels at their 
peripheral terminals. Activation of these receptors or ion channels by 
noxious stimuli generates depolarizing current (or action potential or 
electrical impulse) which is then relayed to the brain for pain perception  
NOCICEPTORS AND AFFERENT NERVES 
High threshold receptors, probably free nerve endings.  
There are several distinct types of Nociceptors:  
¾ Mechano-Nociceptors - generally stimulus specific (intense 
pressure, pinching); mediate fast/first pain, via AS (small 
diameter, myelinated) afferent fibres  
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¾ Polymodal Nociceptors - respond to many different forms of 
noxious stimuli: chemicals, intense heat, etc.; mediate 
slow/second pain, via C (small diameter, unmyelinated) afferent 
fibres  
 
¾ 'Silent' nociceptors - respond only after tissue damage (or 
sensitization) 
 
Nociceptors also differ in their speed of conduction and in their 
capacity to be sensitized during inflammation, injury, and disease. The 
A-delta fiber and the C-fiber nociceptors are the 2 main classes of 
nociceptors. C-fibers are the most common; about 70% of all nociceptors 
are of the C-fiber type. Their axons are unmyelinated and their cell 
bodies are small. When activated, C-fibers conduct action potentials 
slowly, resulting in prolonged burning pain. A-delta fibers have thinly 
myelinated axons with medium- to large-diameter cell bodies. When 
activated, they conduct impulses at a fast rate and produce sharp, 
pricking pain.7 
The nociceptive pain pathway consists of 4 processes: transduction, 
conduction, transmission, and perception.1 Nociception begins with the 
activation of the specific receptors or ion channels in the peripheral 
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terminals of nociceptors by noxious stimuli. The activated receptors 
convert the noxious stimuli into electrical current, a process called 
transduction. The current generated at the peripheral terminals of sensory 
fibers depolarizes the nociceptor membranes generating action 
potentials. The latter are conducted along the nociceptor axons to their 
cell bodies, located in the dorsal root ganglion (DRG) in the spinal cord, 
and then to their central terminals located in the dorsal horn Here, the 
action potentials initiate neurotransmitter release from nociceptor 
central terminals which relay the signal across synapses (transmission) to 
the dorsal horn neurons. The signal is then relayed via ascending 
nociceptive pathways to higher centers in the brain where it is perceived 
as pain (perception).5 
Gate Control Theory 
This was proposed in an attempt to overcome the limitations of a 
specific and direct neural pathway serving pain and nociception.  
The basic concept is that signals elicited in afferent neurons by 
noxious stimuli can be blocked or filtered by a synaptic 'gate' in the 
dorsal horn of the spinal cord. The story is complex and there are many 
controversial features. However, the principle does seem to work in 
practice. even if the precise mechanisms are unsettled.  
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The 'gate' is believed to be located in the substantia           
gelatinosa (SG) of the dorsal horn. Neurons of the SG make connections 
with the terminals of primary afferent fibres and also the dendrites of 
dorsal horn cells. Through either pre-synaptic or postsynaptic inhibition, 
the substantia gelatinosa neurons appear to be able to block (or reduce) 
activation of second order neurons by nociceptive inputs; these 'gating' 
effects of the SG neurons can be activated by:  
(a) inputs in large diameter (A) afferents innervating the injured area. 
(This provides the basis for pain relief by selective activation of large 
diameter afferents, as in transcutaneous electrical nerve stimulation - 
TENS).  
(b) activation of neurons in certain brainstem regions, which send axons 
to the spinal cord.  
CNS Pathways 
Nociceptive afferents synapse with two main groups of neurons in the 
dorsal horn:  
• Lamina I: specific nociceptor neurons  
• Lamina V: multimodal (non-specific) neurons, which receive 
many convergent inputs, including visceral afferents.  
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There are several projection pathways from the spinal cord to the brain:  
(a) A 'specific' pathway, probably the spinothalamic tracts, which 
projects to the somatosensory cortex. This pathway probably serves the 
'sensory' and 'discriminative' aspects of pain.  
(b) A 'non-specific' pathway, probably involving the 
spinoreticulothalamic tracts, which makes widespread and diffuse 
connections with many areas of the forebrain, including the limbic 
system. This system may serve the affective (or 'nasty') aspects of pain.  
VISCERAL PAIN PATHWAY 
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INNERVATION OF STOMACH 
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POSTOPERATIVE  PAIN 
 
¾ Pain is defined as 'an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage. 
¾ It is a complex process influenced by both physiological and 
psychological factors 
 
EFFECTS OF POSTOPERATIVE PAIN 
 
¾ Postoperative pain can affects all organ systems and includes 
¾ Respiratory - reduced cough, atelectasis, sputum retention and 
hypoxaemia 
¾ Cardiovascular - increased myocardial oxygen consumption and 
ischaemia 
¾ Gastrointestinal - decreased gastric emptying, reduced gut motility 
and constipation 
¾ Genitourinary - urinary retention 
¾ Neuroendocrine - hyperglycaemia, protein catabolism and sodium 
retention 
¾ Musculoskeletal - reduced mobility, pressure sores and increased 
risk of DVT 
¾ Psychological - anxiety and fatigue 
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PHARMACOLOGICAL METHODS OF PAIN RELIEF 
SIMPLE ANALGESIA 
¾ Paracetamol is a weak anti-inflammatory agent 
¾ Modulates prostaglandin production in the central nervous system 
¾ Can be administered orally or rectally or intramuscularly 
¾ Best taken on a regular rather than 'as required' basis. 
¾ Overdose results in hepatic necrosis 
¾ Often combined with weak opiates (e.g. dihydrocodeine = Co-
dydramol) 
NON-STEROIDAL ANTI-INFLAMMATORY AGENTS 
¾ Inhibit the enzyme cyclo-oxygenase 
¾ Reduces prostaglandin, prostacyclin and thromboxane production 
¾ Also have weak central analgesic effect 
¾ Often used for their 'opiate sparing' effects 
¾ Side effects include: 
o Gastric irritation and peptic ulceration 
o Precipitation of bronchospasm in asthmatics 
o Impairment of renal function 
o Platelet dysfunction and bleeding 
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OPIATES 
 
¾ Most commonly used drugs are diamorphine, morphine, pethidine 
and pentazocine 
¾ Diamorphine is a prodrug rapidly hydrolysed to morphine and 6-
monoacetyl-morphine 
¾ All act on mu receptors in brain and spinal cord 
¾ Mu 1 receptors are responsible for analgesia 
ROUTES OF OPIATE ADMINISTRATION 
¾ Oral - available for codeine, dihydrocodeine and oramorph 
¾ Subcutaneous - useful for chronic pain relief 
¾ Intramuscular - produces peaks and troughs in pain relief 
¾ Intravenous - reliable but can produce sedation and respiratory 
depression 
¾ Patient-controlled analgesia (PCA) - patient determines own 
analgesic requirement 
o 'Lock-out' period prevents accidental overdose 
o Safe as sedation occurs before respiratory depression 
¾ Epidural or spinal 
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o Lipid soluble opiates (e.g. fentanyl) are normally used 
o Produces good analgesia with reduced risk of side effects 
 
LOCAL ANAESTHETIC AGENTS AND TECHNIQUES 
¾ Can be used by: 
o Wound infiltration 
o Nerve or nerve plexus blockade 
o Epidural infiltration 
o Intrathecal (spinal) administration 
o Intra peridoneal instillation as evidenced by recent trials  
¾ Lignocaine has rapid onset but short duration of action 
¾ Bupivicaine has more prolonged onset but shorter duration of 
action 
 
BUPIVACAINE     
Chemical Structure                                                                                                                
 
Bupivacaine HCl  is chemically designated as 2-
piperidinecarboxamide, 1-butyl-N-(2,6- dimethylphenyl)-, 
monohydrochloride, monohydrate. 
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¾  
¾  
¾  
¾  
¾  
¾  
¾  
¾  
¾  
¾  
¾  
¾  
¾ Bupivacaine chemically and pharmacologically to the aminoacyl 
local anesthetics.  
¾ [It is a homologue of  mepivacaine and is chemically related to 
lidocaine.  
¾ All three of these anesthetics contain an amide linkage between 
the aromatic nucleus and the amino, or piperidine group. They 
differ in this respect from the procaine-type local anesthetics, 
which have an ester linkage. 
 
Pharmacological Actions   
 
         Local anesthetics block the generation and the conduction of 
nerve impulses, presumably by increasing the threshold for electrical 
excitation in the nerve, by slowing the propagation of the nerve impulse, 
and by reducing the rate of rise of the action potential. In general, the 
progression of anaesthesia is related to the diameter, myelination, and 
conduction velocity of affected nerve fibers. Clinically, the order of loss 
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of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) 
proprioception, and (5) skeletal muscle tone. 
          
Systemic absorption of local anesthetics produces effects on the 
cardiovascular and central nervous systems (CNS). At blood 
concentrations achieved with normal therapeutic doses, changes in 
cardiac conduction, excitability, refractoriness, contractility, and 
peripheral vascular resistance are minimal.       
 
Pharmacokinetics:                                                     
    The onset of action with Bupivacaine Hydrochloride is rapid and 
anaesthesia is long lasting. The duration of anaesthesia is significantly 
longer with Bupivacaine Hydrochloride than with any other commonly 
used local anaesthetic. It has also been noted that there is a period of 
analgesia that persists after the return of sensation. The pKa of 
bupivacaine (8.1) is similar to that of lidocaine (7.86). However, 
bupivacaine possesses a greater degree of lipid solubility and is protein 
bound to a greater extent than lidocaine. 
 
 22
Amide-type local anesthetics such as Bupivacaine Hydrochloride 
are metabolized primarily in the liver via conjugation with glucuronic 
acid. Patients with hepatic disease, especially those with severe hepatic 
disease, may be more susceptible to the potential toxicities of the amide-
type local anesthetics. Pipecoloxylidine is the major metabolite of 
Bupivacaine Hydrochloride 
 
 
Various pharmacokinetic parameters of the local anesthetics can 
be significantly altered by the presence of hepatic or renal disease, 
addition of epinephrine, factors affecting urinary pH, renal blood flow, 
the route of drug administration, and the age of the patient.  
 
The half-life of Bupivacaine Hydrochloride in adults is 2.7 hours 
and in neonates 8.1 hours. The kidney is the main excretory organ for 
most local anesthetics and their metabolites. Urinary excretion is 
affected by urinary perfusion and factors affecting urinary pH. Only 6% 
of bupivacaine is excreted unchanged in the urine. 
 
Dosage  
   Maximum dosage: 2 mg/kg.  
      Maximum  in 24 hours is 400 mg 
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ADVERSE REACTIONS 
 
Central Nervous System Reactions: These are characterized by 
excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, 
blurred vision, or tremors may occur, possibly proceeding to 
convulsions. However, excitement may be transient or absent, with 
depression being the first manifestation of an adverse reaction. This may 
quickly be followed by drowsiness merging into unconsciousness and 
respiratory arrest. Other central nervous system effects may be nausea, 
vomiting, chills, and constriction of the pupils. 
Cardiovascular System Reactions: High doses or unintentional 
intravascular injection may lead to high plasma levels and related 
depression of the myocardium, decreased cardiac output, heartblock, 
hypotension, bradycardia, ventricular arrhythmias, including ventricular 
tachycardia and ventricular fibrillation, and cardiac arrest. 
 
Patients over 65 years, particularly those with hypertension, may 
be at increased risk for developing hypotension while undergoing 
anesthesia with Bupivacaine Hydrochloride 
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Contraindications 
 
 
                  Bupivacaine Hydrochloride is contraindicated in obstetrical 
paracervical block anaesthesia. Its use in this technique has resulted in 
fetal bradycardia and death. 
 
                  Bupivacaine Hydrochloride is contraindicated in patients with 
a known hypersensitivity to it or to any local anesthetic agent of the 
amide-type or to other components of Bupivacaine Hydrochloride 
solutions. 
 
Clinically Significant Drug Interactions 
The administration of local anesthetic solutions containing 
epinephrine or norepinephrine to patients receiving monoamine oxidase 
inhibitors or tricyclic antidepressants may produce severe, prolonged 
hypertension. Concurrent use of these agents should generally be 
avoided. In situations when concurrent therapy is necessary, careful 
patient monitoring is essential. 
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[ADRENALINE 
¾ Adrenaline can delay absorption and prolong duration of action 
¾ Should not be used at sites of end-arteries (e.g. ear, fingers, penis) 
¾ Act by reducing transmission along nerve fibres 
¾ Work by blocking sodium channels in the nerve fibres 
¾ Block pain-fibres first but can also result in 
o Neuromuscular blockade 
o Hypotension due to sympathetic blockade 
ASSESSMENT OF PAIN 
¾ Pain is a subjective experience 
¾ Observer assessment of patient behaviour is unreliable 
¾ Pain should be assessed and recorded by: 
o Visual analogue scales 
o Verbal numerical reporting scale 
o Categorical rating scale 
 
VERBAL RATING SCALES 
Verbal pain scales, as the name suggests, use words to describe 
pain. Words such as no pain, mild pain, moderate pain, and severe pain 
are used to describe pain levels. A score from 0 to 3 is assigned to each of 
those word pairs and is used to measure the pain level. 
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NUMERICAL RATING SCALES 
A numerical scale with the range of 0 to 10 is another type of pain 
scale that is used. The words "no pain" appear by the "0" and "worst 
pain possible" is found by the "10." You are asked to choose a number 
from 0 to 10 that best reflects your level of pain. 
VISUAL ANALOGUE SCALES 
VAS or visual analogue scales use a vertical or horizontal line with 
words that convey "no pain" at one end and "worst pain" at the 
opposite end. You are asked to place a mark along the line that indicates 
your level of pain. 
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WONG-BAKER FACES PAIN RATING SCALE 
With the Wong-Baker pain scale, six faces are used that are numbered 0  to 5  
 
 
 
 
 
Face 0 is a happy face (no hurt) 
Face 1 is still smiling (hurts a little bit) 
Face 2 is not smiling or frowning (hurts a little more) 
Face 3 is starting to frown (hurts even more) 
Face 4 is definitely frowning (hurts a whole lot) 
Face 5 is crying although you don't have to cry to choose this face (hurts 
the worst) 
The FACE pain scale would be particularly useful for children who 
may not have verbal skills to express their pain level. 
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BOTTOM LINE ABOUT PAIN SCALES 
 
The aforementioned pain scales focus on the severity of  pain but 
they really don't delve into any other aspect of pain such as qualities of 
pain (sharp, dull, throbbing) or other characteristics of pain (annoying or 
unbearable). There are questionnaires designed for that purpose. The 
questionnaires gather more details about your pain than what can be 
derived from pain scale 
 
FLACC SCALE 
FLACC stands for face, legs, activity, crying and consolability. It is 
an observer rated pain scale. The FLACC pain scale was designed for 
children between the ages of 2 and 7. However, some practitioners in 
adult settings may use the FLACC pain scale for people who are unable 
to communicate their pain. FLACC provides a pain assessment scale 
between 0 and 10. 
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DATE/TIME 
      
Face 
0-No particular expression or smile 
1-Occasional grimace or frown, withdrawn, disinterested 
2-Frequent to constant quivering chin, clenched jaw 
      
Legs 
0 – Normal position or relaxed 
1 – Uneasy, restless, tense 
2 – Kicking, or legs drawn up 
      
Activity 
0 – Lying quietly, normal position, moves easily 
1 – Squirming, shifting back and forth, tense 
2 – arched, rigid or jerking 
      
Cry 
0 – No cry (awake or asleep) 
1 – Moans or whimpers: occasional complaints 
2 – Crying steadily, screams or sobs, frequent complaints
      
Consolability 
0 – Content, relaxed 
1 – Reassured by occasional touching, hugging or being 
talked to, distractible 
2 – Difficult to console or comfort 
      
 
TOTAL SCORE 
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CRIES SCALE  
 
The CRIES pain scale is an observer-rated pain assessment tool 
which is performed by a healthcare practitioner such as a nurse or 
physician. CRIES assesses crying, oxygenation, vital signs, facial 
expression and sleeplessness. The CRIES Pain Scale is generally used 
for infants 6 months old and younger. 
 
THE PNEUMOPERITONEUM 
 
The laparoscopic surgeon should check the position of the patient 
prior to initiating the pneumoperitoneum. Positioning the patient on the 
operating room table is critical and will significantly increase intra-
abdominal visualization.  
Veress needles come in two lengths (120 cm and 150 cm); the 
longer version is obviously for obese patients. 
1. PREPARATION OF THE ABDOMEN:  
The entire, anterior abdominal wall should be prepped from mid 
chest to mid thigh and as lateral as possible. Laparoscopic procedures 
can occasionally become very difficult and may require the insertion of 
additional trocars away from the original operating site. 
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2. GROUNDING THE PATIENT:  
All patients, without exception, should be properly grounded. 
 
3. INSERTION OF THE VERESS NEEDLE:  
The safest access into the intra-abdominal cavity with a Veress 
needle is the umbilical area. The anterior abdominal wall is the thinnest 
at this level and all fascial layers are fused into single fascial planes. 
Thus, the operator should always attempt to insert the Veress needle at 
this site in the virgin abdomen. 
In morbidly obese patients, use two traumatic towel clips or 
Lane’s forceps on each side of the umbilicus to elevate the abdominal 
wall prior to attempt to insert the Veress Needle. 
 
Step 1: Elevating the Anterior Abdominal Wall 
The anterior abdominal wall needs to be elevated in order to 
distance it from the intra-abdominal contents. This is done by grabbing 
the abdominal wall directly under the umbilicus with one hand. If the 
patient is overweight, two towel clamps can be used on each side of the 
umbilicus to achieve the same result.  
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Step 2: The Incision  
A 1 mm incision is made with a # 11 Scalpel at the umbilicus.  
 
Step 3: Inserting the Veress Needle 
The spring function or the retraction capability of the Veress 
Needle is checked. The operating table should be in neutral or flat 
position. The needle is then slowly inserted into the incision. It is angled 
toward the pelvis and advanced. The operator should feel or sense the 
needle passing through two distinct planes.  
The needle is advanced and withdrawn several times. If this is 
done easily and without obstruction, the tip is in proper position. 
 
Step 4: The Saline Test    
      Ten cc of normal saline is injected. This should be done easily. 
The abdominal pull is then released. The Veress needle is then filled to 
the rim with normal saline (or a open syringe can be used). The tension 
on the skin is resumed and the level of saline should immediately drop if 
the needle is in proper intra-abdominal position.  
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Step 5: Initiating the Insufflation 
The Veress needle is then connected to the CO2 insufflation 
tubing (a filter should be used). Insufflation is initiated at a low flow. 
Intra-abdominal pressure recorded at this point should not exceed 8 mm 
Hg. Entry pressure at low flow should be checked immediately while the 
abdominal wall is still elevated. If higher, move the needle around or 
resume the pull on the skin or anterior abdominal wall. If the pressure is 
too high, the Veress needle it is not in the right position and needs to be 
removed. Begin again.  
If in place, switch to high flow and inflate the intra-abdominal 
cavity. 
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USSC VERSASTEP  
The versa – step system is an integrated system combing a Nylon 
stretchable sheath over a Disposable Veress needle. Once inserted, the 
sheath is dilated by inserting the trocar [with a dilator in place]. The real 
advantage of this system is that it has no cutting entry blade, thus 
dramatically decreasing trocar site bleed and the potential for an intra 
abdominal injury. In addition, it creates a smaller fascial defect which 
does not need to be closed [up to 12 mm] 
 
Insertion of the VersaStep System Trocar 
Following insufflation the expandable needle system is inserted, 
the needle is withdrawn leaving the expandable sleeve in place. 
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A tapered blunt dilator is inserted through the sleeve, dilating the 
tract created by the needle. 
                                   
 
              
 
The trocar is maintained in place by the expandable sleeve. 
                                                 
 
 
 
The blunt trocar is used to safely create a Pneumoperitoneum in 
the scarred abdomen. It is inserted by making an initial skin and a 
fascial incision. The fascial incision should be 1 to 1.5 cm in size. A long 
suture (2.0) is placed on each fascial edges. With finger dissection a 
tunnel or an opening into the intraabdominal cavity is gently created. 
The BluntPort* is then inserted. The foamgrip anchoring device is set 
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and secured with the previously placed suture. The insufflation port is 
connected to the insufflation tubing and the pneumoperitoneum created. 
IA 1 cm skin incision is made with a plain scalp. A telescope is 
inserted into the VISIPORT OPTICAL TROCAR and the path of entry 
of the VISIPORT OPTICAL TROCAR into intra-abdominal cavity is 
visualized. The VISISPORT OPTICAL TROCAR is advanced slowly 
through the different planes of the abdominal wall. These planes are cut 
slowly with the blade of the VISIPORT OPTICAL TROCAR (at the tip 
of the instrument) until the intraabdominal cavity is reached. 
Pneumoperitoneum must be created or abdominal wall elevation must 
be performed prior to the insertion of the VISIPORT OPTICAL 
TROCAR 
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   The Termanian Type trocar has greatly improved the safety and 
function of the re-usable trocar. This is the only re-usable trocar we  use. 
It is inserted via a small incision without a pneumoperitoneum and 
rotating  while advancing it. All the abdominal wall layers are well seen 
and visualized. 
                      
 
 
 
 
              A laparoscopy can be performed without significant, deleterious 
effect with intraabdominal pressures up to 20 mm Hg. However, some 
laparoscopic inguinal hernia repairs require higher pressures in the 18 
and 20 mm Hg. range to achieve necessary additional exposure.  
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GENERAL GUIDELINES ARE: 
The best operating intra-abdominal pressures are between 10 to 15 
mm Hg. The visualization of this type of intra-abdominal pressure can 
be further enhanced by modifying the patients’ position (operating table 
position to Trendelenburg to reverse, etc.) 
 
Higher pressures in the 15 to 20 mm Hg range are suboptimal. 
There is a definite correlation with increased postoperative patient 
discomfort and recovery and the use of increased intra-abdominal 
pressure. 
 
Pressures beyond 20 mm Hg are classified as dangerous with 
potential hemodynamic and pulmonary compromise and long term 
effects on the intra-abdominal wall musculature. When such pressures 
are used, some patients will actually report increased abdominal girth 
and a bloating post-operative feeling which persisted for months after 
the procedure in spite of intensive exercise. 
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MATERIALS AND METHODS 
 
Study Design: 
 
Prospective, Randomized, Double – Blind, Placebo – Controlled 
Study.  
 
Sample Size and Randomization 
 
The study included 120 patients with uncomplicated, symptomatic 
cholelithiasis, subacute appendicitis admitted in department of general 
surgery, Coimbatore medical college hospital, Coimbatore between July 
2007 to sep 2009.   
 
All the investigated patients were managed by same team of 
surgeons. The study was approved by the Bioethics Committee of the 
Tamilnadu Dr.M.G.R.Medical University.  
 
The randomization was based on each patient receiving a sealed 
envelope containing a random number selected from the table assigning 
the given individual to one of four groups equal in size (n = 30).  
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¾ Group A received 2 mg/kg of bupivacaine diluted in 60 ml of 
normal saline immediately after the creation of pneumoperitoneum.  
 
¾ Group B was administered 2 mg/kg of bupivacaine diluted in 60 ml 
of normal saline at the end of planned surgical procedure.  
 
¾ Group C received 60 ml of normal saline immediately after the 
creation of pneumoperitoneum.  
 
¾ Group D was given 60 ml of normal saline at the end of planned 
surgical after the creation of pneumoperitoneum. 
 
INCLUSION CRITERIA 
  
¾ Uncomplicated,  Symptomatic Cholelithiasis 
 
¾ Subacute appendicitis  
 
¾ Palamos ligation  
 
¾ Fundoplication  
 
¾ Incisional hernia repair 
 
¾ Age more than 12 years and less than 65 years  
 
¾ ASA grade I and II  
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EXCLUSION CRITERIA 
 
¾ ASA grade III and more  
 
¾ Patients with history of drug allergy  
 
¾ Age less than 12 years and more than 65 years  
 
¾ Pregnancy and lactation 
 
¾ Previous extensive abdominal surgery 
 
¾ Conversion to open surgery  
 
¾ Prolonged administration of nonsteroidal antiinflammatory agents 
(NSAIDs) or other analgesics. 
 
ANAESTHETIC PROTOCAL  
 
The two anesthesiologists involved in the study followed a strict  
protocol. All the individuals were premedicated with intravenous 
pethidine, midazolam, and paracetamol. Anesthesia was induced using 
fentanyl, thiopental, and pancuronium at the body mass–dependent 
dose. After endotracheal intubation, all the patients were provided with 
mechanical ventilation (isoflurane and oxygen mixture) and monitored 
by a capnograph to maintain the carbon dioxide (CO2) level in the 
expired air within the range of 4.0% to 4.5% throughout the procedure. 
In the course of the operation, the patients received 15 ml/ kg of 
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Ringer_s solution in an intravenous infusion. In each case, a gastric tube 
was inserted for the duration of the procedure and removed before its 
termination. To prevent postoperative vomiting, intravenous 
metoclopramide was administered to each patient before awakening. 
 
SURGICAL TECHNIQUE  
 
The procedures were performed by the same team of surgeons of 
surgical unit III involved in the study 
 
The standard French four-port surgical technique was used for 
laparoscopic cholecystectomy. Four ports used for laparoscopic 
appendicectomy Local wound infiltration with 3 to 5 ml of 0.25% 
bupivacaine was routinely administered to all the patients before skin 
incisions. Access to the peritoneal cavity was established using veress 
needle.  
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The first trocar was placed through the umbilicus; and 
pneumoperitoneum with CO2 was created. After introducing two trocars 
the patient was placed in the Trendelenburg position,  
 
The standard suction-irrigation device with the attached 100-ml 
syringe was introduced through the second port cannula directed toward 
the area of dissection.   
In groups A & C the solution was instilled immediately after the 
creation of pneumoperitoneum.  
 
In groups B (bupivacaine) and D (saline), the solution instilled at 
the end of planned surgical procedure before removing the trocars.  
 
An insufflation pressure of 12 mmHg was routinely used 
throughout the operations. The maximum flow of CO2 administered at 
ambient temperature was electronically restricted to 2 l/min, both in the 
course of pneumoperitoneum creation and during further stages of the 
procedure.  
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 LAPAROSCOPIC CHOLECYSTECTOMY 
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LAPAROSCOPIC CHOLECYSTECTOMY 
INTRA PERITONEAL BUPIVACAINE INSTILLATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LAPAROSCOPIC APPENDICECTOMY 
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POST OPERATIVE PAIN ASSESSMENT  
 
All data were entered into a dedicated proforma. A detailed 
statistical analysis included sex, age, body mass index (BMI), ASA 
grade, medical history before operation, duration of surgery, 
postoperative pain assessed by a visual analog scale (VAS), the time 
lapse between the operation and the first demand for analgesics by the 
patient, the total daily analgesia requested throughout the initial 48 h 
after the surgery, and the incidence and intensity of shoulder tip pain.  
 
The primary end points were postoperative pain intensity on the 
VAS 4, 8, 12, 24, and 48 h after LC and the incidence of shoulder tip pain. 
The secondary end points included the latency of nurse-controlled 
analgesia (NCA) activation, the analgesia request rate, and analgesic 
consumption. The number of patients who needed treatment was 
estimated according to the principle of detecting a 20% difference in 
pain intensity with a 90% probability at p assumed to be less than 0.05.  
 
The statistical analysis was based on chisquare and Student t-tests. 
The intensity of postoperative pain was assessed with the patient  at rest 
using VAS, with evaluation at 4, 8, 12, 24, and 48 h postoperatively.  
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Neither the patients nor the nurses knew the relevant group 
assignment. Postoperative pain scores were obtained by an independent 
clinical investigator, who was also blinded. The patients were aware that 
the scale served to analyze the intensity of pain alone, including shoulder 
tip pain, if present, and was not a representation of their generalized 
postoperative discomfort. 
 
 For further analysis, the data were treated as parametric. The 
nursing team recorded episodes of vomiting and nausea. All the patients 
received elective intra muscular  diclofenac analgesia administered on 
demand (NCA), If required, NCA was continued with oral 
administration 12 h postoperatively. All postoperative analgesic 
requirements, including the latency of the first NCA activation, pain 
scores, and relevant clinical parameters, were recorded in a dedicated 
proforma. 
 
The patients were allowed to assume erect position, mobilized, 
and given an oral diet 24 h after the surgery. An overnight hospital stay 
was mandatory for all the patients. All the subjects were seen by the 
surgeons involved in the study during follow-up visits at the outpatient 
surgical department 3 weeks after the operation. 
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OBSERVATIONS AND RESULTS 
 
 
Between Jan 2008 to July 2009  Patients were admitted to our 
surgical department at Coimbatore Medical College Hospital for the 
Management of  uncomplicated Cholelithiasis, sub acute appendicitis, 
fundoplication, Palamos ligation, Incisional hernia repair.  In all, 120 
patients were randomized to four groups equal in size (n = 30). There 
were no significant differences between the groups with  respect to age, 
sex, BMI, ASA grade, and mean duration and intensity of cholelithiasis-
associated complaints (Table 1). Patients who had laparotomy because 
of difficulty and complications were excluded from the study. The mean 
operating time was comparable between the groups.  
 
No major intraoperative complications such as bleeding appeared 
in any of the patients. Gallbladder perforation and resultant bile spillage 
into the subhepatic space occurred in the course of coagulation hook 
cholecystectomy for 1 patient in group A, no patients in group B, 2 
patients in group C, and 1 patient in group D, and was followed by a 
thorough suctioning and rinsing with a small volume of saline. The 
differences between the groups were not significant.  
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The mean intensity of postoperative total abdominal pain as 
assessed by VAS scale was significantly lower in group A than in group B 
patients, by mean values of 20.3% and 15.5% at 4 and 8 h after the 
operation, respectively. This difference became nonsignificant at 12 h 
postoperatively. Pain relief remained significantly higher in group A than 
in group C patients throughout the entire 48-h follow-up period, whereas 
in group C versus group D patients, it was limited to a 24-h period only, 
being nonsignificant at 48 h postoperatively. 
 
None of group A patients reported shoulder tip pain, whereas in 
groups B, C, and D, it was reported, respectively, by 3, 6, and 7 
individuals at 4 h, by 2, 4,and 4 individuals at 8 h, and by 0, 3, and 4 
individuals at 12 h after the operation. This difference was found to be 
significant for group A versus group C at 4 and 8 h after the operation (p 
value  = 0.01 and p value  = 0.03, respectively), whereas borderline 
significance was observed for group A versus group B at 4 h and for 
group A versus group C at 12 h postoperatively (p value = 0.07 in both 
cases).  
 
The latency time from the end of the operation to the first 
activation of NCA after a patient_s demand was significantly longer in 
group A than in group B patients (p value < 0.001). However, this 
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parameter was also significantly higher for the group B patients than for 
the control subjects. The analgesia request rate was significantly lower 
after the operation for group A than for group B (21 vs 27) 
 
 
Table 1. Characteristics of the patients 
No. of Patients Sex (F/M) Age (Years) BMI (Kg/M2) Operation 
Time (Min) 
Group  No. 
patients  
Sex  m / f Age years BMI (Kg 
/ M2 
Operation 
time (min) 
A 30 15/15 35.26 27.3 ± 3.2 56.1 ± 12.7
B 30 17/13 33.76 27.1 ± 3.1 59.5 ± 11.7
C 30 14/16 33.00 26.9 ± 2.9 55.3 ± 12.7
D 30 11/19 34.66 27.6 ± 3.4 55.1 ± 10.6
 
BMI, body mass index There were no significant differences 
between the groups 
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Table 2. Postoperative Pain Score 
Time After Operation (h) A (n = 30) B (n = 30) C (n = 30) D (n = 30)  
Time of 
operation
A (n=30) B (n=30) C (n=30) D (n=30)
4 18.83 ± 4.63 23.63 ± 5.63 33.23 ± 5.44 32.93 ± 4.49
8 20.66 ± 4.08 24.43 ± 5.27 33.83 ± 5.07 34.13 ± 4.42
12 22.26 ± 3.30 23.76 ± 4.86 28.50 ± 3.52 27.06 ± 3.80
24 24.56 ± 2.97 25.00 ± 3.82 29.10 ± 2.91 28.66 ± 3.63
48 24.43 ± 6.08 26.70 ± 3.68 28.80 ± 3.63 29.56 ± 4.07
 
 
CHART 1: VAS  4 HOURS POST OP
18.83
23.63
33.23 32.93
0
5
10
15
20
25
30
35
A (n=30) B (n=30) C (n=30) D (n=30)
TRIAL GROUPS 
VI
S
U
A
L 
A
N
A
LO
G
 S
C
A
LE
 52
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHART 3: VAS  12 HOURS POST OP
22.26 23.76
28.5 27.06
0
5
10
15
20
25
30
A (n=30) B (n=30) C (n=30) D (n=30)
TRIAL GROUPS
VI
SU
A
L 
A
N
A
LO
G
 S
C
A
LE
CHART 2: VAS  8 HOURS POST OP
20.66
24.43
33.83 34.13
0
5
10
15
20
25
30
35
40
A (n=30) B (n=30) C (n=30) D (n=30)
TRIAL GROUPS 
V
IS
U
A
L
 A
N
A
L
O
G
 S
C
A
L
E
 53
 
 
 
 
 
 
 
 
 
 
 
CHART 4: VAS  24 HOURS POST OP
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a Pain scores assessed by the visual analogue scale b None of the 
values for C vs D were significant c Student_s t-test 1090 27 at 4 h and 20 
vs 27 patients at 8 h, respectively). However, this difference became 
nonsignificant at 12 h postoperatively.  
 
Group A had a significantly lower analgesia requirement rate 
throughout the entire 48-h period after the operation than group C, 
whereas the differences in the analgesia request rate between groups B 
and group D were nonsignificant throughout the entire 48-h follow-up 
period. The mean daily NSAID  consumption was significantly lower in 
group A (150.00 mg) than in group B (212.50 mg) on day 1 
postoperatively (p < 0.001). However, on day 2, this difference became  
nonsignificant. Group A versus group C patients and group B versus D 
patients required significantly less analgesia. 
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Table 3. Postoperative Pain Score 
Time after operation p Value (A vs B) p Value (A vs C) p Value  
(B vs D) 
Time of operation 
(HR)  
P Value (A vs 
B) 
P Value (A vs 
C) 
P Value (B vs 
D) 
4 <0.001 <0.001 <0.001 
8 0.003 <0.001 <0.001 
12 0.16 <0.001 0.007 
24 0.62 <0.001 0.01 
48 0.09 0.03 0.19 
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Table 4:  Latency of the first nurse-controlled analgesia request 
(LNCAR) (min), analgesia request (AR) (number of individuals 
who required pain medication), and analgesic consumption 
(AC) mean daily milligrams of diclofenac sodium. 
 
 Time after 
surgery  
A (n = 30) B (n = 30) C (n = 30) D (n = 30)
LNCAr  426.8 ± 57.2 307.0 ± 39.8 109.3 ± 51.0 109.0 ± 46.5
AR 4 h  21 27 28 29
AR 8 h  20 27 28 27
AR 12 h  12 16 20 21
AR 24 h  9 15 18 17
AR 48 h  7 11 15 16
Ac Day 1 150.00 212.50 235.00 235.00
Ac Day 2 17.5 27.5 37.5 40.00
 
 
 58
Table 5.  Latency of the first nurse-controlled analgesia request 
(LNCAR) (min), analgesia request (AR) (number of individuals 
who required pain medication), and analgesic consumption 
(AC) mean daily milligrams of diclofenac sodium. 
 
 Time after 
surgery  
p Value (A vs 
B) 
p Value (A vs 
C) 
p Value (B vs 
D) 
LNCAr  <0.001b <0.001b <0.001b
AR 4 h  0.05 0.02 0.30 
AR 8 h  0.03 0.01 1.0 
AR 12 h  0.30 0.04 0.18 
AR 24 h  0.11 0.02 0.60 
AR 48 h  0.26 0.03 0.19 
Ac Day 1 <0.001 <0.001 <0.001 
Ac Day 2 0.23 0.002 0.004 
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DISCUSSION 
 
Pain after laparoscopic surgery  is considered to arise from three 
main sources: the incision sites within the abdominal wall, the 
pneumoperitoneum in association with both local (peritoneal and 
diaphragmatic stretching, ischemia, acidosis) and systemic (hypercarbia 
causing sympathetic nervous system excitation resulting in amplification 
of the local tissue inflammatory response) changes, and the 
postcholecystectomy wound within the liver (visceral pain).  
 
Total abdominal pain after laparoscopic surgery covers all these 
aspects, with the largest component (50–70%) arising from the incision 
sites, followed by the pneumoperitoneum (20–30%) and cholecystectomy 
(10–20%) . Most laparoscopic operations are performed using a 
pneumoperitoneum with CO2 insufflated into the abdominal cavity. 
Distension of the abdominal cavity by insufflated gas results in 
diaphragmatic stretching that involves shoulder tip pain. The exact 
mechanism of shoulder tip pain has yet to be clarified.  
 
The proposed mechanisms include phrenic nerve neuropraxia of 
short duration, stretching of the subdiaphragmatic fibers by an increased 
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concavity of the diaphragm induced by pneumoperitoneum, loss of 
visceral surface tension after the creation of pneumoperitoneum leading 
to increased weight on the diaphragmatic attachments of the liver, and 
peritoneal damage caused by chemical irritation, ischemia, and 
compression.Because pain after laparoscopic surgery is multifactorial, a 
multimodal approach to postoperative pain management has been 
suggested.  
 
Many different methods have been used successfully to diminish 
the intensity of pain after laparoscopic surgery, including a low-pressure 
pneumoperitoneum, a gasless technique for creating a working space, 
local wound anesthetic infiltration, saline washout , and instillation of 
the subdiaphragmatic region with a local anesthetic . The latter method, 
usually using bupivacaine, has been evaluated in more than a dozen 
trials. However, the results of the cited studies have been conflicting, 
with the majority demonstrating some benefit in terms of pain reduction, 
although the magnitude of this reduction and the duration of the effect 
have been limited. The following observations have been made.  
 
The timing of the intraperitoneal administration of bupivacaine 
seems to be of great importance (before the dissection rather than at the 
end of laparoscopic surgery, as well as the volume of the solution and the 
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appropriate method of solution application, allowing for a good 
propagation of the fluid to both the left and right sides of the diaphragm 
and to the area of dissection to maximize pain reduction. In only a few 
trials was a local anesthetic administered intraperitoneally before 
dissection . Although these trials have demonstrated a benefit in terms of 
pain reduction, in none of them was a real preemptive analgesia used. 
The term ‘‘preemptive analgesia’’ means preoperative administration of 
drugs that modulate the development of the nociception process in the 
intra-and postoperative periods, which results in a reduced postoperative 
requirement for painkillers. Preemptive analgesia prevents the 
establishment of central sensitization to noxious stimuli by the 
decreased enhancement of pain sensation .The current trial was 
designed to evaluate preemptive analgesia with intraperitoneal 
instillation of bupivacaine before the potential nociceptive stimuli 
appearance. 
 
The incidence of shoulder tip pain and the impact of pain intensity 
on the analgesia request rate and analgesia consumption were not 
assessed because all the patients were receiving equal doses of 
analgesics postoperatively. The main advantage of using local 
anesthetics is that they do not have the adverse effects of opioids, which 
may delay recovery and discharge from the hospital. They also are safe, 
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because the range of mean plasma concentration after intraperitoneal 
instillation of plain bupivacaine in the amount of 150 mg is well below 
the toxic concentration level.  
 
The current study has proved that the application of peritoneal 
instillation with bupivacaine immediately after the creation of 
pneumoperitoneum is superior to its use at the end of planned surgical 
procedure the creation of pneumoperitoneum. Findings have 
demonstrated both the primary and secondary end points to be favorable 
for preemptive analgesia immediately after  the creation of 
pneumoperitoneum. However, the total abdominal pain-diminishing 
effect has been rather short lived because significant differences have 
been observed only at 4 and 8 h postoperatively, whereas the reduction of 
shoulder tip pain to zero in the group receiving preemptive analgesia 
immediately after  the creation of pneumoperitoneum has been a huge 
benefit previously unobtainable with any routinely used method.  
 
The differences in total abdominal pain have become 
nonsignificant at 12 h postoperatively, probably because at that time the 
patients have been mobilized and the total abdominal pain has started to 
reflect the incision site pain instead of the diaphragm-related pain, the 
latter being more important in the early postoperative hours. This 
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observation is supported by a longer latency time from the end of the 
operation to the first activation of NCA demanded by the patients in 
group A than by the patients in group B, because during the immediate 
postoperative hours, the diaphragm-related respiratory pain constitutes 
the larger component of the total abdominal pain than the painful 
sensation arising from incision sites.  
 
Moreover, a lower analgesia requirement rate in group A than in 
group B has been observed (a significant difference at 4 and 8 h 
postoperatively), as well as lower analgesic requirements during the 
initial 24 h after the surgery. These effects are probably secondary to a 
decreased central appreciation of pain and a lower level of pain 
expectancy, often leading to an increased analgesia request in 
anticipation of pain.  
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CONCLUSION 
 
 Intraperitoneal  instillation of bupivacaine in saline immediately 
after the creation of pneumoperitoneum has improved the surgical 
outcome after laparoscopic surgery  by significantly diminishing 
abdominal pain, in addition to  elimination of shoulder tip pain. It  also 
decreases the post operative requirement of analgesic drugs.   
 
 65
BIBLIOGRAPHY 
 
1. Barczyn´ ski M, Herman RM (2003) A prospective randomized trial 
on comparison of low-pressure (LP) and standard-pressure (SP)  
pneumoperitoneum for laparoscopic cholecystectomy. Surg Endosc 
17: 533–538 
 
2. Barczyn´ ski M, Herman RM (2004) Low-pressure 
pneumoperitoneum combined with intraperitoneal saline washout 
for reduction of pain after laparoscopic cholecystectomy: a 
prospective randomized study. Surg Endosc 18: 1368–1373 
 
3. Bisgaard T, Klarskov B, Kehlet H, Rosenber J (2003) Preoperative 
dexamethasone improves surgical outcome after laparoscopic  
cholecystectomy: a randomized double-blind placebo-controlled 
trial. Ann Surg 238: 651–660 
 
4. Bisgaard T, Klarskov B, Kristiansen VB, Callesen T, Schulze S, 
Kehlet H, Rosenber J (1999) Multiregional local anesthetic 
infiltration during laparoscopic cholecystectomy in patients 
 66
receiving prophylactic multimodal analgesia: a randomized, double-
blind, placebo-controlled study. Anesth Analg 89: 1017– 1024 
 
5. Cervini P, Smith LC, Urbach DR (2002) The effect of intraoperative 
bupivacaine administration on parenteral narcotic use after 
laparoscopic appendectomy. Surg Endosc 16: 1579–1582 
 
6. Cunniffe MG, McAnena OJ, Dar MA, Calleary J, Flynn N (1998) A 
prospective randomized trial of intraoperative bupivacaine irrigation 
for management of shoulder tip pain following laparoscopy. Am J 
Surg 176: 258–261 
 
7. Elfberg BA, Sjo¨ vall-Mjo¨ berg S (2000) Intraperitoneal bupivacaine 
does not effectively reduce pain after laparoscopic cholecystectomy: 
a randomized, placebo-controlled and double-blind study. Surg 
Laparosc Endosc 6: 357–359 
 
8. Elhakim M, Elkott M, Alin NM, Tahoun HM (2000) Intraperitoneal 
lidocaine for postoperative pain after laparoscopy. Acta Anaesthesiol 
Scand 44: 280–284 
 
 67
9. Fletcher D, Kayser V, Guilbaud G (1996) Influence of timing of 
administration on the analgesic effect of bupivacaine infiltration in 
carrageenin-injected rats. Anaesthesiology 84: 1129–1137 
 
10. Gharaibeh KI, Al-Jaberi TM (2000) Bupivacaine instillation into 
gallbladder bed after laparoscopic cholecystectomy: does it decrease 
shoulder pain? J Laparoendosc Adv Surg Tech A 10: 137–141 1092 
 
11. Hernandez-Palazon J, Tortossa JA, de Nuno la Rosa V, Gimenez-  
Viudes J, Ramirez G, Robles R (2003) Intraperitoneal application of 
bupivacaine plus morphine for pain relief after laparoscopic 
cholecystectomy. Eur J Anaestesiol 20: 891–896 
 
12. Maestroni U, Sarli D, Devito C, Pour Morard Kohan Brunaldi F, 
Anania G, Pavanelli L, Pasqualucci A, Donini A (2002) A new 
         method of preemptive analgesia in laparoscopic cholecystectomy. 
Surg Endosc 16: 1336–1340 
 
13. Mouton WG, Bessell JR, Otten KT, Maddern GJ (1999) Pain after 
laparoscopy. Surg Endosc 13: 445–448 Ng A, Smith G (2002) 
 68
Intraperitoneal administration of analgesia: is this practice of any 
utility? Br J Anaesth 89: 535–537 
 
14. Ng A, Swami A, Smith G, Robertson G, Lloyd DM (2004) Is 
intraperitoneal levobupivacaine with epinephrine useful for 
analgesia following laparoscopic cholecystectomy? A randomized 
controlled trial. Eur J Anaesthesiol 21: 653–657 
 
15. O_Hanlon DM, Colbert S, Ragheb J, McEntee GP, Chambers F, 
Moriarty DC (2002) Intraperitoneal pethidine versus intramuscular 
pethidine for the relief of pain after laparoscopic cholecystectomy: 
randomized trial. World J Surg 26: 1432–1436 
 
16. Papagiannopoulou P, Argiriadou H, Georgius M, Papaziogas 
B,Sfyra E, Kanakoudis F (2003) Preincisional local infiltration of 
levobupivacaine vs ropivacaine for pain control after laparoscopic 
cholecystectomy. Surg Endosc 17: 1961–1964 
 
17. Pascqualucci A, De Angelis V, Contardo R, Colo F, Terrosu 
G,Donini A, Pasetto A, Bresadola F (1996) Preemptive analgesia: A 
 69
randomized, double-blind, placebo-controlled study. Anesthesiology 
85: 11–20  
 
18. Scheinin B, Kellokumpu I, Lindgren L, Haglund C, Rosenberger 
PH (1995) Effect of intraperitoneal bupivacaine on pain after 
laparoscopic cholecystectomy. Acta Anaesthesiol Scand 39: 195–198 
 
19. Szem JW, Hydo L, Barie PS (1996) A double-blinded evaluation of  
intraperitoneal bupivacaine vs saline for the reduction of 
postoperative pain and nausea after laparoscopic cholecystectomy. 
Surg  Endosc 10: 44–48 
 
20. Tsimoyiannis EC, Glantzounis G, Lakkas ET, Siakas P, Jabarin M, 
Tzourou H (1998) Intraperitoneal normal saline and bupivacaine 
infusion for reduction of postoperative pain after laparoscopic 
cholecystectomy. Surg Laparosc Endosc 8: 416– 420 
 
21. Ure BM, Troidl H, Spangenberger W, Neugebauer E, Lefering R, 
Ullmann K, Bende J (1993) Preincisional local anesthesia with 
bupivacaine and pain after laparoscopic cholecystectomy: a double- 
blind randomized clinical trial. Surg Endosc 7: 482–488 
 70
22. Weber A, Munoz J, Garteiz D, Cueto J (1997) Use of 
subdiaphragmatic bupivacaine instillation to control postoperative 
pain after laparoscopic surgery. Surg Laparosc Endosc 7: 6–8  
 
23. Wills VL, Hunt DR (2000) Pain after laparoscopic cholecystectomy. 
Br J Surg 87: 273–284 
 
24. Wne˛k W, Zaja˛czkowska R, Wordliczek J, Dobrogowski J, Korbut R 
(2004) Influence of preoperative ketoprofen administration 
(preemptive analgesia) on analgesic requirement and the level of 
prostaglandins in the early postoperative period. Pol J Pharmacol 56: 
547–552 
 
25. Woolf CJ, Mannion RJ (1999) Neuropathic pain: aethiology, 
symptoms, mechanisms, and management. Lancet 353: 1959– 1964 
 
26. Wordliczek J, Banach M, Garlicki J, Jakowicka-Wordliczek J, 
Dobrogowski J (2002) Influence of pre-or intraoperational use of 
tramadol (preemptive of preventive analgesia) on tramadol 
requirement in the early postoperative period. Pol J Pharmacol 54 : 
639 – 697 1093. 
 71
 
 
 71
PROFORMA FOR POSTOPERATIVE PAIN EVALUATION 
NAME  :      AGE  :  SEX: 
 
ADDRESS :      WEIGHT :                       BMI: 
 
 
I. P. NO :      OCCUPATION: 
 
DOA  :      DOS  :  DOD: 
H/O SMOKING    : 
 
H/O ALCOHOL INTAKE   : 
 
H/O ANY PSYCHIATIRC ILLNESS/ 
CHRONIC AILMENT   : 
 
H/O PREVIOUS DRUG INTAKE  : 
 
COMORBID CONDITIONS   : 
 
 
ANAESTHESIA TYPE   : GA / EPIDURAL 
 
DURATION OF ANAESTHESIA  : 
 
DRUGS USED DURING ANASTHESIA : 
 
 LAPAROSCOPIC PROCEDURE  : 
 
NO. OF PORTS    : 
 
GAS USED FOR PNEUMOPERITONEUM : 
 
INTRA ABDOMINAL PRESSURE  : 
 
DURATION OF SURGERY    : 
INTRAPERITONEAL  
SOLUTION USED    : BUPIVACAINE / NORMALSALINE 
 
TIME OF INSTILLATION   : 
 
POST OP ANALGESIA USED  : 
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NAME :    AGE  : SEX:  IP.NO: 
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NAME :    AGE  : SEX:  IP.NO: 
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GROUP A 
 
S.No Name Age/Sex IP No Ward Date of 
Surgery 
Diagnosis Surgical Procedure
1 Anusiya devi 22/F 2384 FS3 21/01/2008 Intraabdominal 
lymphadenopathy 
Laparoscopic LN Biopsy
2 Prema 35/F 10477 FS3 07/03/2008 Sub Acute Appendicitis Lap. Appendicectomy
3 Sheela 27/F 5430 Special 04/02/2008 Incisional hernia Lap. Hernia repair
4 Neela veni 42/F 5810 FS3 11/02/2008 Calculous Cholecystitis Lap. Cholecystectomy
5 Papathi 55/F 3900 FS3 08/02/2008 Calculous Cholecystitis Lap. Cholecystectomy
6 Saraswathi 52/F 10415 FS3 03/03/2008 Incisional hernia Lap. Hernia repair
7 Rajamani 18/F 19588 FS3 21/04/2008 Sub Acute Appendicitis Lap. Appendicectomy
8 Rena 29/F 43473 FS3 18/08/2008 Sub Acute Appendicitis Lap. Appendicectomy
9 Muthulakshm
i 
30/F 50569 FS3 19/09/2008 Calculous Cholecystitis Lap. Cholecystectomy
10 Revathi 28/F 44739 FS3 08/09/2008 Iliocaecal intussusception Laparocopy & proceed
11 Muthulakshm
i 
21/F 57545 FS3 24/10/2008 Lap. Cholecystectomy Lap. Appendicectomy
12 Pusba 40/F 52045 FS3 06/10/2008 Incisional hernia Lap. Hernia repair
13 JOTHI 
MANI 
30/F 3681 FS3 30/01/09 Sub Acute Appendicitis Lap. Appendicectomy
14 RANI 30/F 72739 FS3 06/03/09 Appendicitis Lap. Appendicectomy
15 Shanthi 52/F 17683 FS2 11/04/2009 Sub Acute Appendicitis Lap appendicectomy
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16 Mohankumar 25/M 26546 MS4/S
3 
15/05/09 Sub Acute Appendicitis Lap. appendicectomy
17 Sudhakar 28/M 67182 MS4/S
3 
12/12/08 Recurrent hernia Lap. TAPP
18 Kumar 38/M 60229 MS4 07/11/2009 Left inguinal hernia Lap. TAPP
19 Nagamanika
m 
13/M 33913 MS5 18/06/2009 Sub Acute Appendicitis Lap. appendicectomy
20 Lazar 49/M 43189 MS5 13/08/2009 Right bubunocoele Lap. TAPP
21 Sentil Raja 25/M 27951 MS5 23/05/2009 Calculous Cholecystitis Lap. Cholecystectomy
22 KJOSEPH 53M 50513 MS4 03/10/08 Calculous Cholecystitis Lap. Cholecystectomy
23 Sunmugam 26/M 20291 MS4/S
3 
17/04/09 Sub Acute Appendicitis Lap. appendicectomy
24 Vijayan 59/M 18250 MS4 11/04/08 Recurrent  inguinal hernia Laparoscopic repair
25 GOPAL 50M 41994 MS4 01/09/08 Hiatus hernia Lap fundoplication
26 VIJAYAN 33M 47919 Ms4 08/09/08 Rt. Varicocle Dlagnostic laproscopy
27 Senthil 33/M 23540 MS5 29/04/2009 Right inguinal hernia Lap. TAPP
28 Kuppusamy 55/M 50461 MS5 12/09/2009 Left inguinal hernia Lap. TAPP
29 Ravichandran 45/M 61678 MS4 28/11/09 B/L inguinal hernia Lap.inguinal
30 Govindaraj 15/M 65862 MS4/S
3 
05/12/08 Congenital hernia Lap. repair
 
 76
 
GROUP B 
 
S.No Name Age/Sex IP No Ward Date of 
Surgery 
Diagnosis Surgical Procedure
1 Arif Begam 35/F 3855 FS3 01/02/2008 Para Umblical hernia Lap. Hernia repair
2 Beena 26/F 6597 FS3 11/02/2008 Recurrent Appendicitis Lap. Appendicectomy
3 Momtaz 24/F 19750 FS3 21/04/2008 Sub Acute Appendicitis Lap. Appendicectomy
4 Saraswathi 40/F 36800 FS3 25/08/2008 Calculous Cholecystitis Lap. Cholecystectomy
5 Rajathi 45/F 44869 FS3 29/08/2008 Sub Acute Appendicitis Lap. Appendicectomy
6 Pusba 40/F 52045 FS3 06/10/2008 Incisional hernia Lap. Hernia repair
7 mariyammal 50/F 55707 FS3 10/11/2009 Sub Actue intestinal 
obstruction 
Laparocopy & proceed
8 Rajeswari 35/F 62340 FS3 12/01/09 Sub Acute Appendicitis Lap. Appendicectomy
9 JAYA 27/F 8047 FS3 20/02/09 Calculous Cholecystitis Lap. Cholecystectomy
10 Priya 22/F 24882 FS2 07/05/2009 Sub Acute Appendicitis Lap.
appendicectomy 
11 Kalpana 13/F 29433 FS2 30/05/2009 Sub Acute Appendicitis Lap.
appendicectomy 
12 Abiba 29/F 40470 FS2 23/07/2009 Sub Acute Appendicitis Lap.
appendicectomy 
13 Devi 38/F 40582 FS2 08/08/2009 Sub Acute intestinal 
obstruction 
Lap.
adhesiolysis 
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14 Veeran 51/M 8005 MS4/S3 16/02/09 Calculus Cholecystits Lap. Cholecystectomy
15 YOGA RAJ 27/M 153 MS4 07/01/08 Sub Acute  Appendicitis Lap. Appendicectomy
16 Eswaran 59/M 10466 MS4 14/03/08 Ca sigmoid colon Laparoscopy & proceed
17 SHAIK 
MOIDEEN   
17/M 14330 MS4 24/03/08 Sub Acute  Appendicitis Lap. Appendicectomy
18 Ponnuraj 27/M 141608 MS4 14/04/08 Indirect hernia Lap. Hernia repair
19 Venu 
prasanth 
25/M  52044 MS4 26/09/08 Calculous Cholecystitis Lap. Cholecystectomy
20 Anilkumar 25/M 30905 MS5 04/06/2009 Sub Acute Appendicitis Lap. appendicectomy
21 Rangaswamy 39/M 33849 Ms5 23/07/2009 Incisional hernia Lap. IPOM
22 Govindarayan 65/M 61699 MS4 21/11/08 B/L inguinal hernia Lap. repair
23 Giripoosaran 30/M 65868 MS4/S3 05/12/08 Sub Acute Appendicitis Lap.
appendicectomy 
24 RAMAN 21/M 64097 MS4/S3 01/12/08 Inguinal Hernia Lap. Repair
25 Samy aya     49/M 61804 MS4 14/11/08 direct inguinal hernia
26 Sentil Kumar 20/M 41810 MS5 13/08/2009 Calculus Cholecystits Lap. Cholecystectomy
27 Thangam 31/M 50607 MS5 19/09/2009 Left inguinal hernia Lap. TAPP
28 Subramaniya
m 
55/M 23569 Special 28/05/2009 Secondaries Liver Diagnostic Laparoscopy
29 Paneerselvam 35/M 26408 MS5 16/05/2009 Right recurrent inguinal 
hernia 
Lap. TAPP
30 GOKUL 13M 50568 MS4 19/09/08 Rt sided Indirect hernia Lap. Hernia repair
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GROUP C 
 
S.No Name Age/Sex IP No Ward Date of 
Surgery 
Diagnosis Surgical Procedure
1 Rubeena 20/F 49153 FS3 15/09/2008 Sub Acute Appendicitis Lap. Appendicectomy
2 sarojini 33/F 70081 FS3 02/01/09 Sub Acute Appendicitis Lap. Appendicectomy
3 lakshmi 48/F 42107 FS3 18/08/2008 G.B.polyp Lap. Cholecystectomy
4 Lakshmi 27/F 47724 FS3 15/09/2008 Calculous Cholecystitis Lap. Cholecystectomy
5 SHANTHI 29/F 3591 FS3 23/01/09 Calculous Cholecystitis Lap. Cholecystectomy
6 Shanthi 43/F 13683 FS2 09/04/2009 Sub Acute Appendicitis Lap.
appendicectomy 
7 Renuka Devi 19/F 24921 FS2 09/05/2009 Sub Acute Appendicitis Lap.
appendicectomy 
8 Mariyamal 50/F 26451 FS2 16/05/2009 Calculous Cholecystitis Lap. Cholecystectomy
9 Amutha vali 13/F 35386 FS2 27/06/2009 Sub Acute Appendicitis Lap.
appendicectomy 
10 Baby Rani 31/F 50530 FS2 10/09/2009 Calculous Cholecystitis Lap. Cholecystectomy
11 Ambika 43/F 53375 FS2 24/09/2009 Calculous Cholecystitis Lap. Cholecystectomy
12 Vijaya 
Lakshmi 
21/F 49007 FS2 05/09/2009 Sub Acute Appendicitis Lap. appendicectomy
13 Chandra 45/F 24807 FS2 07/05/2009 Calculous Cholecystitis Lap. Cholecystectomy
14 ALAGU 40/F 9380 FS3 27/02/09 Calculous Cholecystitis Lap. Hernia repair
15 Mohanapriya 14/F 53453 FS3 10/10/2008 Lap. Cholecystectomy Lap. Appendicectomy
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16 Selvi 30/F 22429 FS3 12/05/2008 Sub Acute Appendicitis Lap. Appendicectomy
17 Asharu deen  16/M 21031 MS4 25/04/08 Sub Acute Appendicitis Lap. Appendicectomy
18 Venu Gopal 30/M 19217 MS5 16/04/2009 Left inguinal hernia Lap. TAPP
19 SUDHKAR 28/M   1435 MS4 18/01/08 Bubunocoele Lap.hernia repair
20 SHANKAR 23/M 23937 MS4 10/05/08 Inguinal hernia Laparoscopic repair
21 Ajesh 43/M 39407 MS5 06/08/2009 Hiatus hernia Lap.Fundoplicatio
22 Sathiya seelan 14/M 6461 MS4/S3 09/02/09 Sub Acute Appendicitis Lap. appendicectomy
23 Sivaswwamy 55/M 49010 MS5 03/09/2009 Right inguinal hernia Lap. TAPP
24 Aaruswamy 42/M 33800 MS5 18/06/2009 Calculous Cholecystitis Lap. Cholecystectomy
25 Vasanth 32/M 6571 MS4 22/02/08 RIF Mass Diagnostic laparoscopy
26 Sundraj 53/M 31112 MS4/S3 08/06/09 Calculous Cholecystitis Lap. Cholecystectomy
27 Selva kumar 42/M  15546 MS4 28/03/08 Umblical hernia Lap. Hernia repair
28 PALANI 45M 50504 MS4 10/10/08 Hydiad Cyst Laparoscopy & proceed
29 Christo 
Clinton John 
15/M 43175 MS5 08/08/2009 Sub Acute Appendicitis Lap.
appendicectomy 
30 Mayil Samy 46/M 64662 MS4 01/12/08 Calculus Cholecystits Lap. Cholecystectomy
 
 
GROUP D 
S.No Name Age/Sex IP No Ward Date of 
Surgery 
Diagnosis Surgical Procedure
1 Gokila raj 49/F 5208 Special 01/02/2008 Calculous Cholecystitis Lap. Cholecystectomy
2 Rathiya 29/F 8597 FS3 22/02/2008 Sub Acute Appendicitis Lap. Appendicectomy
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3 Bagiyalaksh
mi 
25/F 23795 FS3 19/05/2008 Sub Acute Appendicitis Lap. Appendicectomy
4 Ariya 14/F 44902 FS3 29/08/2008 Recurrent Appendicitis Lap. Appendicectomy
5 Papathi 50/F 13057 Special 24/03/2008 Port site hernia Lap. Hernia repair
6 Saraswathy 45/F 54772 FS3 24/11/08 Sub Acute intestinal 
obstruction 
Diagnostic lap & adhesiolysis 
7 SANGEETH
A 
20/F 72318 FS3 09/03/09 Sub Acute Appendicitis Lap. Appendicectomy
8 Moorthyamm
al 
55/F 50417 FS2 17/09/2009 Sub Acute Appendicitis Lap.
appendicectomy 
9 Vijaya 45/F 10436 FS3 29/02/2008 Calculous Cholecystitis Lap. Cholecystectomy
10 VALLIAMM
AL 
47/F 1185 FS3 02/02/09 Calculous Cholecystitis Lap. Cholecystectomy
11 Kayalvizha 18/F 41942 FS2 30/07/2009 Sub Acute Appendicitis Lap.
appendicectomy 
12 Karpakavali 23/F 77448 FS3 25/08/2008 Rt.inguinal hernia TAPP
13 Yaseera 13/F 61854 FS3 14/11/08 Sub Acute Appendicitis Lap. appendicectomy
14 Vijaya 25/F 37867 FS2 09/07/2009 Sub Acute Appendicitis Laroswpic appendicectomy 
15 Anjugam 42/F 50526 FS2 19/09/2009 Sub Acute Appendicitis Lap.
appendicectomy 
16 Rajammal 45/F 54762 FS3 24/10/2008 Calculous Cholecystitis Lap. Cholecystectomy
17 Vanitha 29/F 46145 FS2 22/08/2009 Sub Acute Appendicitis Lap.
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appendicectomy
18 Gandhimathi 25/F 22209 FS2 09/05/2009 Sub Acute Appendicitis Lap.
appendicectomy 
19 Bagiyam 17/F 26424 FS2 14/05/2009 Recurrent Appendicitis Lap. Appendicectomy
20 Sakthivel 39/M 39382 MS4/S3 24/07/09 Sub Acute Appendicitis Lap. appendicectomy
21 Yuvaraj 22/M 32402 MS5 11/06/2009 Acute Appendicitis Lap. appendicectomy
22 Aarusamy 39/M 70074 MS4/S3 05/01/09 B/L inguinal hernia Lap. TAPP
23 Sharman 55/M 9423 MS4/S3 23/02/09 Incisional hernia Lap. Hernia repair
24 HARA 
HARAN 
18M 47734 MS4 08/09/08 Indirect ingunial hernia Lap.repair
25 MURUGAN
ANTHAM 
35/M  155 MS4 18/01/08 Calculous Cholecystitis Lap. Cholecystectomy
26 RAJA 36/M 48489 MS4 05/09/08 Umblical hernia Lap. Hernia repair
27 Chandran 57/M 61730 MS4 14/11/08 Hepatoma Diagnostic Laparoscopy
28 Durai 35/M 26329 MS5 21/05/2009 Calculous Cholecystitis Lap. Cholecystectomy
29 Prakash 23/M 50510 Ms5 12/09/2009 Sub Acute Appendicitis Lap appendicectomy
30 Rajarathinam 65/M 32385 MS5 23/07/2009 Right bubunocoele Lap. TAPP
 
